InMode (INMD) Q1 2026 earnings review
Top-Line Reverses to Growth, But Margins Compress
InMode finally broke a streak of sequential year-over-year revenue declines, posting a 5% top-line increase to $82.0 million in Q1 2026. However, the victory was heavily overshadowed by severe margin compression. Non-GAAP operating margin decelerated sharply from 23% a year ago to 17%, driving a 26% drop in non-GAAP Net Income. Management blamed the contraction on higher cost of goods, recent North American sales restructuring, and subsidiary establishments. Adding to the unease, the sudden resignation of CFO Yair Malca and Board member Dr. Michael Anghel introduces executive instability. With FY26 guidance projecting flat revenue and further margin deterioration, the company is paying a steep price to maintain its market footprint.
🐂 Bull Case
U.S. Capital Equipment revenue jumped 14% YoY to $33.7M, signaling that patient demand and clinic capital expenditures may be thawing in the company's most important geography.
The company maintains a fortress balance sheet with $537.2M in cash and short-term investments, enabling it to aggressively repurchase shares ($34.8M in Q1 alone) while it explores strategic alternatives.
🐻 Bear Case
Despite higher sales, Non-GAAP Gross Margin fell 400 basis points YoY to 75%. The shift toward sourcing lower-margin third-party lasers and persistent tariff impacts are structurally impairing the company's historical 80%+ gross margin profile.
Losing the CFO and a key Board member is a glaring red flag, especially considering the board recently retained Bank of America to explore strategic alternatives following an unsolicited takeover bid.
⚖️ Verdict: 🔴
Bearish. A 5% revenue beat is meaningless if it costs 400-600 basis points of margin to achieve. The structural shift to lower-margin products and executive turnover point to deeper operational struggles ahead.
Key Themes
Operating Leverage is Reversing
InMode historically operated with exceptional efficiency, but 26Q1 marks a stark break in trend. GAAP operating expenses surged 13.6% YoY to $51.5M, vastly outpacing the 5% revenue growth. Sales & marketing climbed, and general & administrative expenses nearly doubled to $5.0M. Management attributed this to North American sales team restructuring and new global subsidiaries. As a result, non-GAAP operating margin plummeted from 23% to 17%.
Consumer Trade-Down Accelerating Non-Invasive Mix
The macroeconomic backdrop—defined by high interest rates and consumer caution—is causing a rapid mix shift. Non-invasive technology revenue surged, representing 22% of total revenue in 26Q1, up dramatically from 10% a year ago. Minimally invasive treatments, which cost thousands of dollars, decelerated to 77% of the mix (from 87%). While this pressures average selling prices, it proves InMode can capture demand from budget-conscious patients.
CFO and Board Resignations Spark Uncertainty
The abrupt, immediate-effect resignations of CFO Yair Malca and Board member Dr. Michael Anghel introduce substantial risk. While standard "no disagreement" clauses were filed, losing top financial leadership is concerning, especially as the company is currently engaged with Bank of America to explore strategic alternatives. A transition period is in place, but this vacuum limits management's ability to execute a turnaround.
Consumables Base Remains Stable
Consumables and service revenue grew 6% YoY to $21.4M. This recurring revenue stream indicates that despite cautious consumer behavior and GLP-1 drug adoption (which management previously flagged as a headwind for fat-reduction procedures), InMode's installed base of physicians continues to perform treatments at a steady clip.
Innovation Focus: Pico and Erbium Lasers
Management continues to execute its strategy of releasing two new platforms per year. The integration of the new Korean-sourced Pico laser and the proprietary Morpheus/Erbium YAG combination expands the Total Addressable Market into the 'bread and butter' laser segment. While this third-party sourcing is actively compressing gross margins, it is a necessary driver to keep clinic upgrade cycles moving in a saturated market.
Aggressive Share Repurchases Continue
Capital allocation remains heavily skewed toward buybacks. The company repurchased 2.55 million shares at an average price of $13.65 in 26Q1, deploying $34.8 million. While this supports the stock price in the near term, it also signals a lack of compelling M&A targets despite management's previous statements about pivoting cash usage toward acquisitions.
Other KPIs
Decelerating. International sales dipped 4% YoY from $28.1M in 25Q1. This contrasts sharply with management's prior narrative of international operations acting as the primary growth engine offseting U.S. weakness. U.S. capital equipment, conversely, grew 14% to $33.7M.
Decelerating sharply. Net income fell 36% YoY from $18.2 million. This is a clear indicator that volume growth at the top line is completely detached from bottom-line profitability due to structural cost increases.
Guidance
Stable. The midpoint of $370M implies completely flat growth compared to FY25 actuals ($370.5M). It indicates management does not expect the 5% YoY growth seen in Q1 to persist through the remainder of the year.
Decelerating. This is a severe step down from FY25's 79%. The compression explicitly confirms that the shift toward lower-margin, third-party sourced lasers and ongoing tariff impacts are permanent structural headwinds, not temporary blips.
Decelerating. The midpoint ($1.355) represents a roughly 15% decline from FY25's non-GAAP EPS of $1.60. Earnings recession is expected to deepen despite heavy share repurchases artificially supporting the per-share metrics.
Key Questions
CFO Departure Context
What drove the sudden departure of the CFO in the middle of a strategic alternatives review, and how does this impact the timeline of the Bank of America evaluation?
Margin Floor on Third-Party Lasers
With non-GAAP gross margin guided down to the mid-70s, what is the ultimate margin floor as third-party sourced products like the Pico laser make up a larger portion of the revenue mix?
U.S. vs International Reversal
U.S. capital equipment grew 14% while International shrank 4%. Is this a sustainable reversal of the trend seen throughout 2025, or merely a timing irregularity regarding product launches?
Class Action Lawsuit Status
The motion to dismiss the second amended complaint is pending. How is the company planning for potential financial impacts, and are legal fees associated with this defense materially impacting G&A expenses?